Literature DB >> 18245466

Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells.

Esther Suswam1, Yanyan Li, Xiaowen Zhang, G Yancey Gillespie, Xuelin Li, John J Shacka, Liang Lu, Lei Zheng, Peter H King.   

Abstract

Malignant gliomas are highly aggressive tumors of the central nervous system that rely on production of growth factors for tumor progression. Vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and tumor necrosis factor-alpha, for example, are up-regulated in these tumors to promote angiogenesis and proliferation. RNA stability, mediated through adenine and uridine-rich elements (ARE) in the 3' untranslated region, is a critical control point for regulating these growth factors. RNA half-life is predominantly governed by a balance between stabilizing and destabilizing factors that bind to ARE. We have previously shown that the stabilizing factor HuR is overexpressed in malignant gliomas and linked to RNA stabilization of angiogenic growth factors. Here, we report that the destabilizing factor tristetraprolin (TTP) is also ubiquitously expressed in primary malignant glioma tissues and cell lines. In contrast to benign astrogliotic tissues, however, the protein was hyperphosphorylated, with evidence implicating the p38/mitogen-activated protein kinase (MAPK) pathway. Conditional overexpression of TTP as a transgene in malignant glioma cells led to RNA destabilization of IL-8 and VEGF and down-regulation of protein production. Analysis of in vivo RNA binding indicated a shift of mRNA toward ectopic TTP and away from endogenous HuR. This biochemical phenotype was associated with a decrease in cell proliferation, loss of cell viability, and apoptosis. We postulate that hyperphosphorylation of TTP via p38/MAPK promotes progression of malignant gliomas by negatively regulating its RNA destabilizing function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245466     DOI: 10.1158/0008-5472.CAN-07-2751

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells.

Authors:  Federico Bolognani; Anne-Isabelle Gallani; Lena Sokol; David S Baskin; Nicole Meisner-Kober
Journal:  J Neurooncol       Date:  2011-09-21       Impact factor: 4.130

Review 2.  The roles of TTP and BRF proteins in regulated mRNA decay.

Authors:  Sandhya Sanduja; Fernando F Blanco; Dan A Dixon
Journal:  Wiley Interdiscip Rev RNA       Date:  2011 Jan-Feb       Impact factor: 9.957

Review 3.  Inflammation: cytokines and RNA-based regulation.

Authors:  Deborah J Stumpo; Wi S Lai; Perry J Blackshear
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

4.  Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin.

Authors:  Hyun Hee Lee; Mai-Tram Vo; Hyo Jeong Kim; Unn Hwa Lee; Chae Won Kim; Hong Kyeung Kim; Myoung Seok Ko; Won Hyuck Lee; Seung Joo Cha; Young Joo Min; Dae Hwa Choi; Ho Seok Suh; Byung Ju Lee; Jeong Woo Park; Wha Ja Cho
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

5.  The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer.

Authors:  Rajat Banerjee; Elizabeth A Van Tubergen; Christina S Scanlon; Robert Vander Broek; Joel P Lints; Min Liu; Nickole Russo; Ronald C Inglehart; Yugang Wang; Peter J Polverini; Keith L Kirkwood; Nisha J D'Silva
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

Review 6.  Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action.

Authors:  Seth A Brooks; Perry J Blackshear
Journal:  Biochim Biophys Acta       Date:  2013-02-18

7.  Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival.

Authors:  Rohit Upadhyay; Sandhya Sanduja; Vimala Kaza; Dan A Dixon
Journal:  Int J Cancer       Date:  2012-09-18       Impact factor: 7.396

Review 8.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.

Authors:  Esther A Suswam; John J Shacka; Kiera Walker; Liang Lu; Xuelin Li; Ying Si; Xiaowen Zhang; Lei Zheng; L Burt Nabors; Heping Cao; Peter H King
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

10.  The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase.

Authors:  Sandhya Sanduja; Vimala Kaza; Dan A Dixon
Journal:  Aging (Albany NY)       Date:  2009-09-10       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.